ECI 301
Alternative Names: ECI301Latest Information Update: 30 Dec 2021
At a glance
- Originator Effector Cell Institute
- Developer Effector Cell Institute; National Institute on Aging
- Class Antineoplastics; Chemokines; Proteins
- Mechanism of Action Leukocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Liver cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Cancer in USA (IV)
- 28 Apr 2018 No recent reports of development identified for phase-I development in liver cancer in Japan (IV)
- 01 Apr 2016 Phase-I development is ongoing